ד"ר רונן ארבל

Zucker, Roy; Wolff-Sagy, Yael; Ramot, Noga; Raviv, Yuval; Lavie, Gil; Netzer, Doron; Hammerman, Ariel; Arbel, Ronen. Examining the Patterns of Mpox Vaccine Uptake in a Vulnerable Population. Sexually Transmitted Diseases

Nadarajah R, Wu J, Hogg D, Raveendra K, Nakao Y, Nakao K, Arbel R, Haim M, Zahger D, Parry J, Bates C, Cowan JC, Gale CP. Development, validation and outcomes associated with a risk prediction algorithm for incident atrial fibrillation: retrospective national cohort study of 2 081 139 individuals. Europace. 2023 May 24;25(Suppl 1):euad122.543.

Alnsasra H, Tsaban G, Solomon A, Khalil F, Aboalhasan E, Azab AN, Azuri J, Hammerman A, Arbel R. Dapagliflozin versus empagliflozin in patients with chronic kidney disease. Front Pharmacol. 2023 Aug 4;14:1227199

Alnsasra, H., Tsaban, G., Solomon, A. et al. Effect of Dapagliflozin Versus Empagliflozin on Cardiovascular Death in Patients with Heart Failure Across the Spectrum of Ejection Fraction: Cost per Outcome Analysis. Am J Cardiovasc Drugs 23, 323–328 (2023).

Arbel, Ronen et al. The superiority of bivalent over monovalent booster vaccines. The Lancet Infectious Diseases, Volume 23, Issue 12, 1324 - 1325

Azuri, J, Hammerman, A, Aboalhasan, E, Sluckis, B, Arbel, R. Liraglutide versus semaglutide for weight reduction—a cost needed to treat analysis. Obesity (Silver Spring). 2023; 31( 6): 1510- 1513

Azuri, J, Hammerman, A, Aboalhasan, E, Sluckis, B, Arbel, R. Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis. Diabetes Obes Metab. 2023; 25( 4): 961- 964.

HADAR DUSKIN-BITAN, AMIR TIROSH, TANYA BECKENSTEIN, DORON NETZER, RONEN ARBEL, ALON PERETZ; 1457-P: Analysis of Type 1 Diabetes Trends in Israel. Diabetes 20 June 2023; 72 (Supplement_1): 1457–P.

Nadarajah R, Wu J, Arbel R, et alRisk of atrial fibrillation and association with other diseases: protocol of the derivation and international external validation of a prediction model using nationwide population-based electronic health recordsBMJ Open 2023;13:e075196.

Nadarajah R, Wu J, Hogg D, et alPrediction of short-term atrial fibrillation risk using primary care electronic health recordsHeart Published Online First: 09 February 2023.

Nadarajah, R., Younsi, T., Romer, E., Raveendra, K., Nakao, Y., Nakao, K., Shuweidhi, F., Hogg, D., Arbel, R., Zahger, D., Iakobishvili, Z., Fonarow, G.C., Petrie, M.C., Wu, J. and Gale, C.P. (2023), Prediction models for heart failure in the community: a systematic review and meta-analysis. Eur J Heart Fail. Accepted Author Manuscript.

Nadarajah, R., Younsi, T., Romer, E., Raveendra, K., Nakao, Y.M., Nakao, K., Shuweidhi, F., Hogg, D.C., Arbel, R., Zahger, D., Iakobishvili, Z., Fonarow, G.C., Petrie, M.C., Wu, J. and Gale, C.P. (2023), Prediction models for heart failure in the community: A systematic review and meta-analysis. Eur J Heart Fail, 25: 1724-1738.

R Arbel, M Yechezkel, E Shmueli, D Yamin, Risk of myocarditis requiring hospitalization following Covid-19 mRNA booster vaccinations, European Heart Journal, Volume 44, Issue Supplement_2, November 2023, ehad655.1827,

Roy Zucker, Gil Lavie, Yael Wolff-Sagy, Noa Gur-Arieh, Hila Markovits, Wiessam Abu-Ahmad, Erez Battat, Noga Ramot, Tanya Beckenstein, Guy Carmeli, Avner Mark-Amir, Gal Wagner-Kolasko, Amos Edry, Hadar Duskin-Bitan, Shlomit Yaron, Alon Peretz, Ariel Hammerman, Doron Netzer, Ronen Arbel, Risk assessment of human mpox infections: retrospective cohort study, Clinical Microbiology and Infection, Volume 29, Issue 8, 2023, Pages 1070-1074

Wolff Sagy Y, Zucker R, Hammerman A, et al. Real-world effectiveness of a single dose of mpox vaccine in males. Nature Medicine. 2023 Jan.

Wu J, Nadarajah R, Nakao YM, et alIncident cardiovascular, renal, metabolic diseases and death in individuals identified for risk-guided atrial fibrillation screening: a nationwide cohort studyOpen Heart 2023;10:e002357

G Tsaban, H Alnsasra, A El Nasasra, E Aboalhasan, J Azuri, A Hammerman, R Arbel, Colchicine for secondary prevention of cardiovascular disease, a cost per outcome analysis, European Journal of Preventive Cardiology, Volume 29, Issue Supplement_1, May 2022, zwac056.054,

Tsaban, G., Alnsasra, H., El Nasasra, A. et al. Aspirin with Low-Dose Ticagrelor or with Low-Dose Rivaroxaban for Secondary Prevention: A Cost per Outcome Analysis. Am J Cardiovasc Drugs 22, 677–683 (2022).

Ronen Arbel, Ph.D., Yael Wolff Sagy, Ph.D., et al (2022) Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge. N Engl J Med 2022; 387:790-798

Ronen Arbel, Candace Makeda Moore, Ruslan Sergienko, Joseph Pliskin, How many lives do COVID vaccines save? Evidence from Israel, American Journal of Infection Control, Volume 50, Issue 3, 2022, Pages 258-261

H Alnsasra, G Tsaban, E Aboalhasan, A El Nasasra, J Azuri, A Hammerman, R Arbel, Sacubitril/valsartan versus in empagliflozin heart failure with preserved ejection fraction, European Journal of Preventive Cardiology, Volume 29, Issue Supplement_1, May 2022, zwac056.022,

Ariel Hammerman, Ph.D., Ruslan Sergienko, et al. (2022) Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19. N Engl J Med 2022; 386:1221-1229

Ariel Hammerman, Candace Makeda Moore, Enis Aboalhasan, Joseph Azuri, Ronen Arbel, Usefulness of Empagliflozin Versus Oral Semaglutide for Prevention of Cardiovascular Mortality in Patients With Type 2 Diabetes Mellitus, The American Journal of Cardiology, Volume 170, 2022, Pages 128-131

Ariel Hammerman, Candace Makeda Moore, Enis Aboalhasan, Joseph Azuri & Ronen Arbel (2022) Oral versus subcutaneous semaglutide for prevention of major adverse cardiovascular events: cost per outcome analysis of SUSTAIN-6 and PIONEER-6, Postgraduate Medicine

Arbel, R.; Pliskin, J. Vaccinations versus Lockdowns to Prevent COVID-19 Mortality. Vaccines 2022, 10, 1347.

Arbel, R.; Pliskin, J. Vaccinations versus Lockdowns to Prevent COVID-19 Mortality. Vaccines 2022, 10, 1347.

Arbel, R., Sergienko, R., Friger, M. et al. Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years. Nat Med 28, 1486–1490 (2022).

Arbel R, Sagy YW, Zucker R, et al. Vaccine Effectiveness of Modified Vaccinia Ankara in Human Monkeypox. Research Square; 2022.

Hammerman, A., Azuri, J., Aboalhasan, E. et al. Dapagliflozin Versus Sacubitril–Valsartan to Improve Outcomes of Patients with Reduced Ejection Fraction and Diabetes Mellitus. Am J Cardiovasc Drugs (2021).

Arbel R, Aboalhasan E, Hammerman A, et al. DAPAGLIFLOZIN FOR PREVENTION OF ATRIAL FIBRILLATION EVENTS IN PATIENTS WITH TYPE TWO DIABETES: NUMBER NEEDED TO TREAT AND ASSOCIATED COSTS. J Am Coll Cardiol. 2021 May, 77 (18_Supplement_1) 335.

Ronen Arbel, Ariel Hammerman, et al. (2021) BNT162b2 Vaccine Booster and Mortality Due to Covid-19. N Engl J Med 2021; 385:2413-2420

Ronen Arbel, Enis Aboalhasan, Ariel Hammerman, Joseph Azuri, Icosapent Ethyl for Primary Versus Secondary Prevention of Major Adverse Cardiovascular Events in Hypertriglyceridemia: Value for Money Analysis, The American Journal of Medicine, Volume 134, Issue 7, 2021, Pages e415-e419

Ronen Arbel, Enis Aboalhasan, Ariel Hammerman, Joseph Azuri, Usefulness of Sodium-Glucose Cotransporter 2 Inhibitors for Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus,
The American Journal of Cardiology, Volume 150, 2021, Pages 65-68

Ronen Arbel, Enis Aboalhasan, Ariel Hammerman, Joseph Azuri, Dapagliflozin vs. sacubitril-valsartan for prevention of heart failure events in non-diabetic patients with reduced ejection fraction: a cost per outcome analysis, European Journal of Preventive Cardiology, 2020;, zwaa136,

Arbel, R., Aboalhasan, E., Hammerman, A. et al. Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Heart Failure Events in Patients with Type 2 Diabetes Mellitus: A Cost Per Outcome Analysis. Clin Drug Investig 40, 665–669 (2020).

Arbel, R., Sergienko R., Hammerman, A., Greenberg-Dotan, S, Batat E., Avnery O., Greenberg, D. & Ellis, MH. (2019) Direct anticoagulation and mortality in atrial fibrillation. Heart 105(19):1487-1492.(IF: 5.1; Ranked Q1 in Cardiology).

Arbel R, Sergienko R, Hammerman A, et alDirect oral anticoagulation and mortality in moderate to high-risk atrial fibrillationHeart 2019;105:1487-1492.

Arbel, R., Sergienko R., Hammerman, A., Greenberg-Dotan, S, Batat E., Avnery O., & Ellis, MH. (2019). Effectiveness and Safety of Off-Label Dose-Reduced Direct Oral Anticoagulants in Atrial Fibrillation. American Journal of Medicine 132(7):847-855. (IF: 5.1; Ranked Q1 in Medicine)

Arbel, R., Hammerman, A., & Azuri, J. (2018). Usefulness of empagliflozin versus liraglutide for prevention of cardiovascular mortality. American Journal of Cardiology 122, 981-984. (Impact Factor: 3.2; Ranked Q1 in Cardiology)

Arbel, R., Hammerman, A., & Azuri, J. (2018). Usefulness of Ezetimibe Versus Evolocumab as Add-on Therapy for Secondary Prevention of Cardiovascular Events in Patients with Type 2 Diabetes Mellitus. American Journal of Cardiology 123 (8), 1273-1276. (Impact Factor: 3.2; Ranked Q1 in Cardiology)

Arbel, R. & Greenberg, D. (2017). Using lower-cost statins improves outcomes for normal cholesterol non-diabetic patients. Expert Review of Pharmacoeconomics & Outcomes Research. 17, 495-501. (Impact Factor: 1.8; Ranked Q2 in health policy)

Arbel, R., Hammerman A., Triki N. & Greenberg, D. (2016) PCSK9 inhibitors may improve cardiovascular outcomes—can we afford them? International Journal of Cardiology, 220, 242–245. (Impact Factor: 4.0; ranked Q1 in Cardiology)

Arbel, R. & Greenberg, D. (2016). Rethinking cost-effectiveness in the era of zero healthcare spending growth. International Journal for Equity in Health, 15, 1-7. (5-year Impact factor: 2.4; ranked Q1 in Health Policy)